<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913039</url>
  </required_header>
  <id_info>
    <org_study_id>2019-03-03</org_study_id>
    <nct_id>NCT03913039</nct_id>
  </id_info>
  <brief_title>Reduction of Prostate Biopsy Morbidity</brief_title>
  <official_title>Reduction of Prostate Biopsy Morbidity and Hospitalization Through a Modified Biopsy Protocol Bundle and Region-specific Antibiogram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate biopsy is typically performed via either the transrectal or transperineal approach.&#xD;
      This study is a case-control study being done to determine if a novel prostate biopsy&#xD;
      protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and&#xD;
      broad antibiotic prophylaxis will reduce infectious complications and hospital readmission&#xD;
      compared to current biopsy practices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective multi-center cohort case-control study comparing a novel&#xD;
      transperineal prostate biopsy protocol integrating measures to reduce post procedural&#xD;
      infection (Cases) to traditional transrectal prostate biopsies (Controls). Eligible subjects&#xD;
      will be identified through administrative records in the Urology clinics affiliated with&#xD;
      Maimonides Medical Center. Eligible patients will be counseled about the risks and benefits&#xD;
      of participation and offered enrollment into the study. Demographic data including age,&#xD;
      comorbidities and past medical history will be extracted from the medical record.&#xD;
&#xD;
      Men meeting inclusion/exclusion criteria will be prospectively enrolled. The novel&#xD;
      transperineal protocol will include the following: (Cases)&#xD;
&#xD;
        1. Transperineal biopsy approach with avoidance of rectal flora&#xD;
&#xD;
        2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where&#xD;
           clinically indicated&#xD;
&#xD;
        3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria&#xD;
&#xD;
        4. Multi-antibiotic prophylaxis&#xD;
&#xD;
        5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary,&#xD;
           region-specific antibiotic resistance patterns.&#xD;
&#xD;
      Traditional biopsy protocol includes: (Controls)&#xD;
&#xD;
        1. Transrectal approach&#xD;
&#xD;
        2. Standard 12-core template&#xD;
&#xD;
        3. Surgeon-specific antibiotic prophylaxis&#xD;
&#xD;
        4. Urine culture, prostate tissue culture and FQR rectal swab culture to define&#xD;
           contemporary, region-specific antibiotic resistance patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinically significant post-biopsy complications</measure>
    <time_frame>30 Days</time_frame>
    <description>1. Rate of any clinically significant post-biopsy complications including infectious complications and hospital readmissions within 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Number of individual complications within 30 days</measure>
    <time_frame>30 Days</time_frame>
    <description>1. Individual complications within 30 days including urinary retention, hematuria, urinary tract infection, hospitalization</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>transperineal protocol</arm_group_label>
    <description>Transperineal biopsy approach with avoidance of rectal flora&#xD;
MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated&#xD;
Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria&#xD;
Multi-antibiotic prophylaxis&#xD;
Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional biopsy</arm_group_label>
    <description>Transrectal approach&#xD;
Standard 12-core template&#xD;
Surgeon-specific antibiotic prophylaxis&#xD;
Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transperineal biopsy Protocol</intervention_name>
    <description>Transperineal biopsy approach with avoidance of rectal flora&#xD;
MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated&#xD;
Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria&#xD;
Multi-antibiotic prophylaxis&#xD;
Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.</description>
    <arm_group_label>transperineal protocol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males with clinical indication for a prostate biopsy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients greater than 18 years of age&#xD;
&#xD;
          -  Indication for prostate biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients&#xD;
&#xD;
          -  Male patients under 18 years of age&#xD;
&#xD;
          -  No indication for prostate biopsy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Assessment of Prostate Cancer treatment - - only males qualify.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ariel Schulman, MD</last_name>
    <phone>7182836903</phone>
    <email>ASchulman@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Meeder</last_name>
    <phone>7182837253</phone>
    <email>smeeder@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Schulman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Ariel Schulman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03913039/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

